Profile data is unavailable for this security.
About the company
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
- Revenue in USD (TTM)455.99m
- Net income in USD-285.01m
- Incorporated--
- Employees2.20k
- LocationLegend Biotech Corp2101 Cottontail LaneSOMERSET 08873United StatesUSA
- Phone+1 (732) 317-5050
- Websitehttps://investors.legendbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | 362.80m | -205.49m | 5.81bn | 638.00 | -- | 18.08 | -- | 16.01 | -3.42 | -3.42 | 5.85 | 5.07 | 0.3141 | 0.8694 | 5.88 | 553,887.00 | -17.79 | -29.92 | -21.66 | -34.06 | 96.19 | -- | -56.64 | -116.65 | 3.65 | -16.38 | 0.5471 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Cytokinetics, Inc. | 3.13m | -545.28m | 6.33bn | 423.00 | -- | 58.22 | -- | 2,018.68 | -5.37 | -5.37 | 0.0309 | 0.9236 | 0.0027 | -- | 6.36 | 7,408.98 | -47.34 | -43.14 | -51.07 | -47.22 | -- | -- | -17,398.82 | -540.47 | -- | -12.85 | 0.8578 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Ionis Pharmaceuticals Inc | 813.46m | -365.74m | 6.74bn | 927.00 | -- | 23.68 | -- | 8.28 | -2.53 | -2.53 | 5.63 | 1.81 | 0.2873 | 0.4264 | 29.47 | 877,517.80 | -12.92 | -6.30 | -14.43 | -7.44 | 98.58 | 98.75 | -44.96 | -21.23 | 7.51 | -- | 0.8288 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Nuvalent Inc | 0.00 | -173.59m | 7.05bn | 115.00 | -- | 10.97 | -- | -- | -2.78 | -2.78 | 0.00 | 9.84 | 0.00 | -- | -- | 0.00 | -31.08 | -- | -32.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Halozyme Therapeutics, Inc. | 873.30m | 337.29m | 7.50bn | 373.00 | 22.97 | 25.90 | 17.91 | 8.59 | 2.58 | 2.58 | 6.68 | 2.29 | 0.4621 | 1.20 | 3.79 | 2,341,298.00 | 17.85 | 18.22 | 19.11 | 21.97 | 79.95 | 79.05 | 38.62 | 39.36 | 6.21 | -- | 0.8385 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Exelixis Inc | 2.01bn | 349.99m | 7.54bn | 1.31k | 22.62 | 3.55 | 20.02 | 3.74 | 1.17 | 1.17 | 6.54 | 7.43 | 0.6809 | 3.23 | 6.40 | 1,537,386.00 | 11.83 | 8.86 | 13.38 | 9.91 | 96.06 | 96.30 | 17.38 | 15.43 | 4.21 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Revolution Medicines Inc | 742.00k | -519.21m | 7.59bn | 443.00 | -- | 4.65 | -- | 10,224.94 | -3.65 | -3.65 | 0.0051 | 9.77 | 0.0005 | -- | 0.5912 | 1,962.96 | -36.03 | -29.76 | -38.48 | -32.59 | -- | -- | -69,973.99 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Viking Therapeutics Inc | 0.00 | -96.75m | 7.81bn | 28.00 | -- | 8.48 | -- | -- | -0.9379 | -0.9379 | 0.00 | 8.31 | 0.00 | -- | -- | 0.00 | -14.36 | -21.91 | -14.78 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Tempus AI Inc | 595.57m | -790.20m | 8.40bn | 2.30k | -- | 85.49 | -- | 14.10 | -8.23 | -8.23 | 4.34 | 0.6367 | -- | -- | -- | -- | -- | -- | -- | -- | 51.85 | -- | -121.04 | -- | 3.52 | -28.75 | 0.8183 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 455.99m | -285.01m | 8.89bn | 2.20k | -- | 7.67 | -- | 19.49 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -16.63 | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.08bn | 431.79m | 10.63bn | 20.00k | 24.58 | 2.85 | 13.68 | 2.61 | 8.37 | 8.37 | 78.94 | 72.13 | 0.5188 | 8.23 | 5.22 | 203,888.80 | 5.67 | 6.46 | 6.52 | 7.62 | 35.98 | 36.99 | 10.93 | 11.58 | 1.21 | 4.97 | 0.39 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 2.03bn | 339.64m | 11.34bn | 5.80k | 34.39 | 14.81 | 30.82 | 5.58 | 10.63 | 10.63 | 63.59 | 24.69 | 1.22 | -- | 7.05 | 344,075.90 | 20.43 | 13.94 | 45.87 | 23.18 | 28.52 | 28.84 | 16.74 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Neurocrine Biosciences, Inc. | 2.12bn | 339.20m | 11.95bn | 1.50k | 35.74 | 4.76 | 32.84 | 5.64 | 3.31 | 3.31 | 20.64 | 24.87 | 0.7163 | 0.9811 | 4.95 | 1,513,929.00 | 11.46 | 9.77 | 13.74 | 12.19 | 98.28 | 98.51 | 16.00 | 14.79 | 4.08 | 6.10 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Sarepta Therapeutics Inc | 1.50bn | 47.30m | 12.13bn | 1.31k | 305.22 | 11.25 | 139.35 | 8.06 | 0.4168 | 0.4168 | 15.40 | 11.30 | 0.4595 | 0.4948 | 5.04 | 1,145,352.00 | 1.44 | -21.63 | 1.76 | -25.75 | 88.29 | 86.65 | 3.14 | -77.05 | 3.19 | -- | 0.5324 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Data as of Sep 20 2024. Currency figures normalised to Legend Biotech Corp's reporting currency: US Dollar USD
32.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 16.01m | 8.80% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 11.49m | 6.31% |
| RA Capital Management LPas of 30 Jun 2024 | 7.51m | 4.13% |
| HHLR Advisors Ltd.as of 30 Jun 2024 | 6.64m | 3.65% |
| Westfield Capital Management Co. LPas of 30 Jun 2024 | 4.77m | 2.62% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.45m | 1.90% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 2.62m | 1.44% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 2.33m | 1.28% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 2.16m | 1.19% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 1.96m | 1.08% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
